U
14.20
0.42 (3.05%)
| Previous Close | 13.78 |
| Open | 14.00 |
| Volume | 1,017,054 |
| Avg. Volume (3M) | 1,114,973 |
| Market Cap | 767,891,968 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 59.41 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 |
| Operating Margin (TTM) | -2,815.25% |
| Diluted EPS (TTM) | -4.38 |
| Quarterly Revenue Growth (YOY) | -81.50% |
| Total Debt/Equity (MRQ) | 1,522.46% |
| Current Ratio (MRQ) | 11.99 |
| Operating Cash Flow (TTM) | -166.25 M |
| Levered Free Cash Flow (TTM) | -122.89 M |
| Return on Assets (TTM) | -15.64% |
| Return on Equity (TTM) | -241.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | uniQure N.V. | Bullish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.09% |
| % Held by Institutions | 91.95% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 392.96%) | Buy |
| Median | 52.50 (269.72%) | |
| Low | 35.00 (Chardan Capital, 146.48%) | Buy |
| Average | 52.50 (269.72%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 17.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 08 Sep 2025 | 35.00 (146.48%) | Buy | 17.43 |
| 29 Aug 2025 | 35.00 (146.48%) | Buy | 16.33 | |
| HC Wainwright & Co. | 08 Sep 2025 | 70.00 (392.96%) | Buy | 17.43 |
| 05 Sep 2025 | 70.00 (392.96%) | Buy | 17.95 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Sep 2025 | Announcement | uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease |
| 29 Jul 2025 | Announcement | uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress |
| 22 Jul 2025 | Announcement | uniQure to Announce Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |